A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Tivozanib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 27 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
- 22 Oct 2016 Primary endpoint has been met. (Progression-free survival from study disease will be evaluated using imaging scans (CT or MRI)), according to results published in the Annals of Oncology.